Related Experiment Video
Updated: Jul 15, 2025
08:14
Author Spotlight: Developing Innovative Therapeutic Strategies for Hemorrhagic Shock Research
Published on: March 22, 2024
1.4K
[Novel therapeutic agents for hemolytic anemia]
1Department of Hematology and Oncology, Graduate School of Medicine, Osaka University.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology
|October 4, 2023
Summary
Novel anti-complement agents are emerging for complementopathies like paroxysmal nocturnal hemoglobinuria (PNH) and cold agglutinin disease. These therapies target complement system abnormalities, offering new treatment options for hemolytic anemias.
Area of Science:
- Immunology
- Hematology
- Pharmacology
Context:
- Complement system abnormalities (complementopathies) are increasingly recognized as causes or exacerbating factors in various diseases.
- Paroxysmal nocturnal hemoglobinuria (PNH) exemplifies a complement-mediated disease, making it a key target for novel therapies.
- The development of anti-complement agents marks a significant advancement in treating complement-related disorders.
Purpose:
- To provide an overview of novel anti-complement agents.
- To highlight their application in treating hemolytic anemias, including PNH and cold agglutinin disease.
- To discuss the expanding therapeutic landscape for complement-targeted treatments.
Summary:
- Complementopathies and complement-related diseases necessitate targeted therapeutic strategies.
- Anti-complement agents, such as anti-C5 monoclonal antibody eculizumab and anti-C1s antibody sutimlimab, are demonstrating efficacy.
- These agents are crucial for managing conditions like PNH and cold agglutinin disease, with ongoing development for broader applications.
Impact:
- Advances in anti-complement therapies offer new hope for patients with debilitating hemolytic anemias.
- The success of eculizumab and sutimlimab paves the way for a new class of drugs targeting the complement cascade.
- Further research and development in anti-complement agents promise expanded treatment options for a range of complement-mediated diseases.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
729
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
729
01:28Role of Hematopoietic Growth Factors
1.4K
Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
Thrombopoietin (TPO), mainly released by the liver,...
1.4K
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
02:45Blood Transfusion and Agglutination
10.9K
Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
10.9K
01:27Disorders of Erythrocytes
963
Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
963
01:24Disorders of Hemostasis
973
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
973